Clinical trials: Diabete Type 2
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Type 2 Diabetes
My Diabetes, My Community
Older adults with diabetes are a highly vulnerable population that suffers the highest rates of cardiovascular and microvascular complications as well as adverse drug events such as hypoglycemia.
- Trial name
- NCT04970810
- Testing
- My Diabetes Goal, My Diabetes Goal + CommunityRx
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- University of Chicago
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.
- Trial name
- NCT00372060
- Testing
- sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, Obesity
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
What are the benefits of undergoing Roux-en-Y gastric bypass surgery in improving type 2 diabetes outside of weight loss alone?
- Trial name
- Microbiome (NCT02762708)
- Testing
- Roux-en-Y Gastric Bypass (RYGB), Caloric Restriction, Exendin-9,39
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Diabetes Mellitus
Evaluation of a Primary Type 2 Diabetes Prevention Programme
A type 2 diabetes prevention programme, named PREDIAS was developed. It consists of 12 lessons delivered as group sessions. Die efficacy of PREDIAS was studied in a randomized controlled study with 12 month follow up.
- Trial name
- PREDIAS (NCT00707447)
- Testing
- PREDIAS, Control
- Where
- Germany
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Forschungsinstitut der Diabetes Akademie Mergentheim
Type 2 Diabetes Mellitus
Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy
- Trial name
- NCT01864174
- Testing
- Metformin XR, Metformin IR
- Where
- 156 sites in United States, Canada and 8 more
- Volunteers
- 1,736 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2…
- Trial name
- TRINITY (NCT03231709)
- Testing
- Trelagliptin, Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background…
- Trial name
- NCT01986855
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02390050
- Testing
- Bexagliflozin tablets
- Where
- 50 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Diabetes Mellitus, Type 2
A Study of LY2922470 in Healthy Participants and Participants With Diabetes
The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to…
- Trial name
- NCT01746017
- Testing
- LY2922470
- Where
- Singapore
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- PIONEER 5 (NCT02827708)
- Testing
- semaglutide
- Where
- 117 sites in United States, Denmark and 6 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- NCT01620489
- Testing
- liraglutide
- Where
- 97 sites in United States, France and 4 more
- Volunteers
- 279 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.